A5062597953- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Antifungal resistance and susceptibility
- Fungal Infections and Studies
- Monoclonal and Polyclonal Antibodies Research
- Acute Myeloid Leukemia Research
- Bone and Joint Diseases
- Vascular Tumors and Angiosarcomas
- Chronic Lymphocytic Leukemia Research
- Hepatitis C virus research
- Plant Pathogens and Fungal Diseases
- Infectious Diseases and Mycology
- Hemoglobinopathies and Related Disorders
- Hepatitis B Virus Studies
- Hepatitis Viruses Studies and Epidemiology
- Rabies epidemiology and control
- CNS Lymphoma Diagnosis and Treatment
- Liver Disease Diagnosis and Treatment
- Microbial infections and disease research
- Multiple Myeloma Research and Treatments
- Chronic Myeloid Leukemia Treatments
- Cancer Treatment and Pharmacology
- Porphyrin Metabolism and Disorders
- Viral-associated cancers and disorders
- Parvovirus B19 Infection Studies
Genmab (Denmark)
2023-2025
Statens Serum Institut
2020-2022
Rigshospitalet
2019-2022
Copenhagen University Hospital
2021
Capital Region of Denmark
2012
Roskilde Sygehus
2011
Herlev Hospital
2010
Patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) have poor outcomes. Gemcitabine + oxaliplatin (GemOx) rituximab, a standard salvage therapy, yields complete response (CR) rates of approximately 30% and median overall survival (OS) 10-13 months. disease fare worse, CR rate 7% for subsequent therapies OS 6 Epcoritamab, CD3xCD20 bispecific antibody approved the treatment R/R DLBCL after ≥2 therapy lines, has shown promising safety efficacy in various...
Isavuconazole (ISZ) is used in the treatment of aspergillosis and mucormycosis. The purpose this study was to evaluate therapeutic drug monitoring (TDM) ISZ samples from a clinical setting performed at Statens Serum Institut. Materials/methods: serum concentrations were determined by fluorescent detection on UHPLC. Serum-ISZ (s-ISZ) results included compared those serum-voriconazole (s-VRZ) 33 month period March 2017. Clinical data obtained for patients receiving ISZ. range initially 2–10...
Abstract Background Azole resistance complicates treatment of patients with invasive aspergillosis an increased mortality. in Aspergillus fumigatus is a growing problem and associated human environmental azole use. Denmark has considerable highly efficient agricultural sector. Following reports on A. from Danish patients, the ministry health requested prospective national surveillance azole‐resistant particularly that origin. Objectives To present data first 2 years programme. Methods Unique...
Azole resistant (azole-R) Aspergillus is an increasing challenge worldwide. Patients with cystic fibrosis (CF) are at risk of colonisation and disease due to a favourable lung environment for microorganisms. We performed nationwide study in 2018 azole-non-susceptible CF-patients compared data from two prior studies. All airway samples mould isolates patients monitored the CF-centres Denmark (RH, Jan-Sept AUH, Jan-Jun) were included. Classical species identification (morphology...
As part of a national surveillance programme initiated in 2004, fungal blood isolates from 2016–2018 underwent species identification and EUCAST susceptibility testing. The epidemiology was described compared to data previous years. In 2016–2018, 1454 unique were included. fungaemia rate 8.13/100,000 inhabitants 8.64, 9.03, 8.38 2004–2007, 2008–2011, 2012–2015, respectively. Half the cases (52.8%) involved patients 60–79 years old incidence highest males ≥70 old. Candida albicans accounted...
7037 Background: Gemcitabine + oxaliplatin (GemOx) is commonly used with rituximab to treat relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL); however, outcomes are suboptimal: 33% complete response (CR) rate; 5 mo median progression-free survival (PFS); 10 overall (OS; Cazelles et al, Leuk Lymphoma 2021). We report additional efficacy and safety results of epcoritamab GemOx in difficult-to-treat R/R DLBCL (EPCORE™ NHL-2 phase 1/2 trial, NCT04663347). Methods: Adults CD20...
Early prefibrotic myelofibrosis (early PMF) is a diagnosis that clinically and histologically mimic essential thrombocythemia (ET), but important to distinguish from ET, polycythemia vera (PV) primary (PMF) due its different prognosis clinical evolution. In this study, we assessed the allele burden of JAK2V617F in bone marrow biopsies patients with these chronic myeloproliferative neoplasms. We correlated our findings amount phosphorylated STAT3 (P-STAT3) STAT5 (P-STAT5) megakaryocyte nuclei...
Mucormycosis is a life threatening infection in patients with haematological disease. We introduced Mucorales-PCR and an aggressive, multidisciplinary management approach for mucormycosis during 2016–2017 evaluated patient outcomes 13 diagnosed treated 2012–2019. Management principle: repeated surgical debridement until biopsies from the resection margins were clean as defined by negative Blankophor microscopy, (both reported within 24 h), cultures. Cultured isolates underwent EUCAST E.Def...
Background: In myelodysplastic syndrome (MDS), anemia often leads to red blood cell transfusion dependency and iron overload (IOL). Serum ferritin (SF) is used as a surrogate marker for IOL. IOL can lead liver failure. Transient elastography (TE) also known fibroscan an easy noninvasive procedure stiffness measurements (LSM). Methods: Sixty patients with either MDS, chronic myelomonocytic leukemia dysplastic features, acute myeloid progressed from MDS or myelodysplastic/ myeloproliferative...